1. Report Overview
1.1 Global Pre-Filled Injection Devices Market Overview
1.2 Pre-Filled Injectable Devices Market Segmentation
1.3 Top Pre-Filled Injectable Devices Market: An Overview
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Pre-Filled Injectable Devices
2.1 What are Pre-Filled Injectable Devices?
2.2 Classification of Companies in the Pre-Filled Injectable Devices Market
2.2.1 Pen Injectors and Autoinjectors
2.2.2 Benefits and Weaknesses of Pre-Filled Injectors
2.3 The Pre-Filled Injection Devices Market 2016-2026
2.4 Contract Manufacturing as a Sector of the Pre-Filled Injectable Devices Market
2.5 Demand on the Western Market is the Highest
2.6 Key Trends in the Pre-Filled Injection Device Market 2016-2026
2.6.1 Increased Market Consolidation
2.6.2 Increased Development of Biologics and Biosimilars
2.6.3 Rise In At Home Care
2.6.4 Greater Demands for Safety Leading Innovation
2.6.5 Threat from Other Drug Delivery Technologies
3. Leading Companies in the Pre-Filled Syringes Manufacturing Market 2016-2026
3.1 Becton, Dickinson, & Co (BD)
3.1.1 BD: Broad Portfolio of Syringe Products
3.1.1.1 BD Hypak: The First Glass Pre-Filled Syringe Worldwide
3.1.1.2 BD Sterifill
3.1.1.3 BD Soluvia
3.1.1.4 BD Uniject on the Emerging Market
3.1.1.5 BD Physioject Autoinjector
3.1.1.6 BD Nano 4mm Pen Needles
3.1.1.7 BD Pen Injectors: BD Liquid Dry Injector and BD Reusable Pen
3.1.1.8 BD Vystra Disposable Pen
3.1.1.9 BD Neopak
3.1.1.10 BD Proprietary Syringe Safety Systems
3.1.1.11 The BD Emerald Portfolio
3.1.2 New Product Launches Planned
3.1.3 BD Acquires Safety Syringes
3.1.4 BD’s Pre-Filled Injection Historical Revenue 2014-2015
3.1.5 Major Acquisitions and Focus on Core Competencies
3.1.6 BD’s Main Strategic Goals
3.1.7 BD: Trend for Strategic Partnering
3.1.8 BD SWOT Analysis, 2016-2026
3.1.8.1 Collaboration and Expansion: Strategies for Growth and Rebranding
3.1.8.2 BD Medical Revenue Forecast 2015-2026
3.2 Gerresheimer
3.2.1 Pre-Filled Syringe Manufacture at Gerresheimer
3.2.1.1 RTF (Ready-To-Fill) Glass Syringes at Gerresheimer
3.2.1.2 ClearJect RTF Plastic Syringes at Gerresheimer
3.2.1.3 New German-made RTF ClearJect Syringe Combines the RTF Concept with Plastic
3.2.2 Pen Injector Manufacture at Gerresheimer
3.2.3 Gerresheimer Historical Revenue 2014-2015
3.2.4 Strategic Sale of Glass Tubing Business: Company Focus on Medical Devices and Primary Packaging
3.2.5 Strong Growth in the Plastics and Devices Division with a Focus on Modernisation
3.2.6 Standardisation as a Strategy
3.2.7 Gerresheimer SWOT Analysis, 2016-2026
3.2.7.1 Rapid Growth Planned for Emerging Markets
3.2.7.2 Gerresheimer is Well-Placed for Biologics Growth and More Stringent Regulatory Changes
3.2.7.3 Gerresheimer Pen Injector Market Revenue Forecast 2015 to 2026
3.3 Schott
3.3.1 Schott Markets Glass and Plastic Pre-Filled Syringes
3.3.1.1 Glass Syringes at Schott: Forma 3s and syriQ
3.3.1.2 TopPac Polymer Syringes
3.3.1.3 InJentle Syringes for Sensitive Drug Products
3.3.1.4 Other New Innovations at Schott
3.3.2 Schott Historical Revenue
3.3.3 Expansion in Developed and Emerging Markets
3.3.3.1 Growth in the Emerging Market
3.3.4 Schott SWOT Analysis, 2016-2026
3.3.4.1 Schott’s Emerging Market Strategy
3.4 Nipro Medical Corporation
3.4.1 Overview of Nipro’s Pre-Filled Syringe Portfolio
3.4.2 New Products at Nipro
3.4.3 Nipro is Expanding Globally
3.4.4 Nipro SWOT Analysis, 2016-2026
3.4.4.1 Responding to Rising Diabetes Incidence
3.5 Stevanato Group/Ompi
3.5.1 Ompi Markets Glass Pre-Filled Syringes and Cartridges
3.5.1.1 EZ-Fill Syringe
3.5.1.2 Extra High Quality (XQ) Syringes
3.5.1.3 Acquisitions and Innovations at Ompi
3.5.2 Focused on Growth for Cartridges and Vials Manufacturing Especially in Emerging Markets
3.5.3 Ompi SWOT Analysis, 2016-2026
3.5.3.1 Ompi’s Products for the Biologics Market
3.5.3.2 Investing to Expand Capacity and Deal with Increasing Demand
3.6 Pre-Filled Syringe Manufacturers: Competitor Analysis 2016 to 2026
3.6.1 The Need for Advanced Safety Systems
3.6.2 Meeting the Demands of Biologics and Biosimilar Developers
3.6.3 Product Portfolio Diversity
3.6.4 What Demand is there in Emerging Markets?
3.7 High Barriers to Market Entry Will Limit Competition to 2026
3.8 Other Manufacturers of Interest in this Market
3.8.1 Unilife
3.8.1.1 Unilife’s Many Collaborations
3.8.1.2 Unilife’s Historical Revenue 2013-2015
3.8.2 Revolutions Medical: A Disposable Syringe Manufacturer Entering the Pre-Filled Market
3.8.3 Weigao Group Pharmaceutical Packaging Products Company
3.8.3.1 Weigao’s Historical Revenue 2013-2015
3.8.3.2 Weigao Pre-Filled Syringes Revenue Forecast 2015-2026
3.8.4 Roselabs Group
4. Leading Companies in the Pre-Filled Injectable Components Manufacturing Market
4.1 Aptar Stelmi is a Pharma Packaging Specialist
4.1.1 Aptar Stelmi’s Pre-Filled Syringe Components
4.1.1.1 Aptar Stelmi’s Rigid Needle Shields
4.1.2 Aptar: Strategically Increasing Market Access to the Autoinjector Market
4.1.3 Aptar Stelmi’s Expansion and Innovations
4.1.4 Aptar Stelmi’s Historical Revenue 2013-2015
4.1.5 Aptar Stelmi SWOT Analysis, 2016-2026
4.1.5.1 Regional Expansion is Important for Continued Growth
4.1.6 Aptar Stelmi Revenue Forecast 2015-2026
4.2 Dätwyler Holding
4.2.1 Dätwyler’s Pre-Filled Syringe Components
4.2.1.1 Omniflex Coating: An Alternative to Silicone Oil
4.2.2 Demand from Insulin Manufacturers Drives Revenue Growth 2013-2015
4.2.3 Dätwyler is Focused on Strategic Acquisition and Expansion
4.2.4 Growth in Emerging Markets
4.2.5 Dätwyler SWOT Analysis, 2016-2026
4.2.6 Dätwyler Healthcare Revenue Forecast 2015-2026
4.3 West Pharmaceutical Services
4.3.1 West Manufactures Syringes and Syringe Components
4.3.1.1 Daikyo Crystal Zenith: Licensed from Daikyo Seiko
4.3.1.2 MixJect for Lyophilised Drugs
4.3.1.3 West’s Self-Injection Systems
4.3.1.4 West Markets Three Safety Systems
4.3.1.5 Innovation and Investment at West
4.3.2 Recent Financial Performance
4.3.3 Collaborations with Big Pharma for Product Development
4.3.4 Expansion at West
4.3.5 West SWOT Analysis, 2016-2026
4.3.6 West Pharmaceutical Revenue Forecast 2015-2026
4.4 Pre-Filled Syringe Component Manufacturers: Competitor Analysis 2016-2026
4.4.1 How Can Component Manufacturers React to Increased Safety Demands?
4.4.2 Other Manufacturers of Interest in this Market
4.4.2.1 Tip-top: Three Safety Products for Pre-Filled Syringes
4.4.2.2 Nemera: Formed from Rexam’s Sale of Healthcare Division
4.4.3 Entering the Autoinjector Market
4.4.4 Component Manufacturers Following Pre-Filled Syringe Manufacturers to Emerging Markets
5. Leading Companies in the Pen Injector and Autoinjector Manufacturing Market 2016-2026
5.1 Haselmeier
5.1.1 Haselmeier Markets Five Injection Systems
5.1.1.1 Axis Pen Systems
5.1.1.2 i-Pen: Haselmeier’s Insulin Pen Injector
5.1.2 Company Growth in Germany and India
5.1.3 Haselmeier SWOT Analysis, 2016-2026
5.2 Owen Mumford
5.2.1 Autoinjector and Pen Injector Overview
5.2.1.1 Autoject
5.2.1.2 Autopen
5.2.1.3 SimpleJect: Designed for RA Patients
5.2.2 Innovative Products to Drive Growth
5.2.3 Expanding in Established and New Markets
5.2.4 Owen Mumford SWOT Analysis 2016-2026
5.3 SHL Group
5.3.1 SHL Manufactures a Broad Range of Injection Devices
5.3.1.1 DAI Autoinjectors
5.3.2 SHL Group Continues to Grow in Taiwan
5.3.3 SHL Group SWOT Analysis, 2016-2026
5.4 Ypsomed
5.4.1 Product Portfolio
5.4.1.1 YpsoPen
5.4.1.2 ServoPen
5.4.1.3 UnoPen
5.4.1.4 LyoTwist Injectors for Lyophilised Drugs
5.4.1.5 Ypsomed Markets Two Autoinjectors
5.4.1.6 Expansion at Ypsomed: Current and Future Plans
5.4.2 Ypsomed: Financial Performance 2013-2015
5.4.3 A Focus on Diabetes
5.4.4 Ypsomed SWOT Analysis, 2016-2026
5.4.5 Ypsomed Delivery Devices Revenue Forecast 2015-2026
5.5 Pen Injector and Autoinjector Manufacturers: Competitor Analysis 2015-2026
5.5.1 A Competitive Market 2016-2026
5.5.2 Other Manufacturers of Interest in this Market
5.5.2.1 Bespak Injectables
5.5.3 How Are Companies Differentiating Their Autoinjectors?
5.5.4 Rising Demand in At-Home Care
5.5.4.1 Specific Demands in RA and MS
5.5.5 Contract Manufacturing for Autoinjectors
6. Leading Companies in the Contract Pre-Filled Injectable Devices Manufacturing Market 2016-2026
6.1 Catalent is the World’s Largest CMO
6.1.1 Pre-Filled Syringe Contract Manufacturing Capabilities
6.1.2 Catalent Offers an Autoinjector
6.1.3 Innovations at Catalent
6.1.4 Catalent Pharma Solutions: Financial Performance 2013-2015
6.1.5 Expanding Filling Capacity for Clinical Trial Materials
6.1.6 Possible Acquisition of Catalent by Lonza
6.1.7 Catalent SWOT Analysis 2016-2026
6.1.8 Catalent Pre-Filled Syringe and Cartridge Filling Revenue Forecast 2015-2026
6.2 Hospira One2One
6.2.1 Hospira and the Pre-Filled Injection Device Industry
6.2.1.1 iSecure Syringe: Hospira’s Pre-Filled Injection System
6.2.2 Hospira: Uncertain Future
6.2.3 Hospira SWOT Analysis, 2016-2026
6.2.4 Hospira One2One: Pre-Filled Injection Device Revenue Forecast 2015-2026
6.3 Vetter Pharmaceutical
6.3.1 Vetter is an Injectable Manufacturing Specialist
6.3.2 Vetter’s Ten Year Expansion Plan
6.3.3 New Services and Collaborations
6.3.4 Vetter SWOT Analysis 2016 to 2026
6.3.5 Outlook for Vetter: Pre-Filled Injection Device Revenue Forecast 2015-2026
6.4 The Competitive Outlook for Leading CMOs in the Market 2016-2026
6.4.1 Biologics, Lyophilisation, and Dual-Chamber Syringes
6.4.2 An Increasingly Competitive Market
6.4.3 Important of Keeping Up with Regulations
6.5 Other Pre-Filled Syringe Contract Manufacturers 2016
6.5.1 Laboratorios Farmacéuticos ROVI
6.5.1.1 ROVI CM’s Pre-Filled Syringe Capabilities
6.5.2 Albany Molecular Research Inc (AMRI): Strategic Acquisitions
6.5.2.1 AMRI’s Recent Financial Performance
6.5.3 Boehringer Ingelheim
7. Research Interviews
7.1 Interview with Gerresheimer
7.1.1 Drivers and Restraints in the Pre-Filled Devices Market
7.1.2 Pre-Filled Medical Device Development at Gerresheimer
7.1.3 Future Trends in the Pre-Filled Medical Devices Market
8. Conclusions
8.1 Outlook for the Pre-Filled Injection System Market 2016-2026
8.2 Outlook for Leading Pre-Filled Injection System Manufacturers 2016-2026
8.2.1 How Will Leading Companies’ Revenues Grow to 2026?
8.3 The Future of the Pre-Filled Medical Devices Market
Table 1.1 Currency Exchange Rates
Table 2.1 Total Pre-Filled Device Manufacturing Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 2.2 Pre-Filled Injection Device Market by Region, 2015
Table 2.3 Pre-Filled Injection Device Market: STEP Analysis, 2016-2026
Table 2.4 Selected Recent Acquisitions in the Pre-Filled Injection Devices Industry
Table 3.1 BD Overview, 2016
Table 3.2 BD Historical Revenue by Division ($m), 2014
Table 3.3 BD Revenue by Division ($m), AGR (%), 2014-2015
Table 3.4 Medical Division Revenue ($m), 2014-2015
Table 3.5 BD: Pharmaceutical Systems Revenue ($m), AGR (%), CAGR (%), 2013-2015
Table 3.6 BD Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 3.7 BD Pharmaceutical Systems Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 3.8 Gerresheimer Employees by Region, 2015
Table 3.9 Gerresheimer Overview, 2016
Table 3.10 Gerresheimer Revenue by Division ($m), AGR ($), CAGR ($), 2014-2015
Table 3.11 Gerresheimer Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 3.12 Gerresheimer Pen Injectors: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 3.13 Schott Overview, 2016
Table 3.14 Schott Revenue ($m), AGR (%), CAGR (%), 2013-2015
Table 3.15 Schott Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 3.16 Nipro Overview, 2016
Table 3.17 Nipro Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 3.18 Stevanato Group/Ompi Overview, 2016
Table 3.19 Ompi Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 3.20 Pre-Filled Syringes: Leading Product Comparisons, 2016
Table 3.21 Leading Pre-Filled Syringe Manufacturers: Comparative Product Ranges, 2016
Table 3.22 Unilife Overview, 2016
Table 3.23 Unilife: Revenue, ($m), AGR (%), CAGR (%), 2013-2015
Table 3.24 Revolutions Medical: RevVac Distribution Agreements, 2011-2014
Table 3.25 Weigao Group Pharmaceutical Packaging Products Company Overview, 2016
Table 3.26 Weigao: Pre-Filled Syringes Revenue ($m), AGR (%), CAGR (%), 2013-2015
Table 3.27 Weigao: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 3.28 Roselabs Group Overview, 2016
Table 4.1 Aptar Stelmi Overview, 2016
Table 4.2 Aptar Stelmi: Revenue ($m), AGR (%), CAGR (%), 2013-2015
Table 4.3 Aptar Stelmi Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 4.4 Aptar Stelmi: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 4.5 Dätwyler Overview, 2016
Table 4.6 Dätwyler: Sealing Solutions Revenue ($m), AGR (%), CAGR (%), 2013-2015
Table 4.7 Dätwyler Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 4.8 Dätwyler Healthcare: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 4.9 West Pharmaceutical Services Overview, 2016
Table 4.10 West: Selected Pharmaceutical Industry Partners, 2016
Table 4.11 West: Revenue by Division ($m), 2013-2015
Table 4.12 West Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 4.13 West: Pre-Filled Syringe and Device Revenue ($m), AGR (%), CAGR (%), 2013-2015
Table 4.14 West Pharmaceuticals: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 4.15 Tip-top Overview, 2016
Table 4.16 Nemera Overview, 2016
Table 5.1 Haselmeier Overview, 2016
Table 5.2 Selected Partners for the i-Pen, 2016
Table 5.3 Haselmeier Pre-Filled Injection Devices: SWOT Analysis, 2016-2016
Table 5.4 Owen Mumford Overview, 2016
Table 5.5 Selected Autoject Range Products, 2016
Table 5.6 Owen Mumford Pre-Filled Injection Devices: SWOT Analysis, 2016 to 2026
Table 5.7 SHL Group Overview, 2016
Table 5.8 SHL Group: Pen Injectors and Autoinjectors, 2016
Table 5.9 SHL Group Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 5.10 Ypsomed Overview, 2016
Table 5.11 Ypsomed: Pen Injectors and Autoinjectors, 2016
Table 5.12 Selected Pharmaceutical Partners for Ypsomed’s Pen Injectors, 2013
Table 5.13 LyoTwist Injectors Available, 2016
Table 5.14 Ypsomed: Revenue by Division ($m), CAGR (%), 2013-2015
Table 5.15 Ypsomed Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 5.16 Ypsomed Delivery Devices: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 5.17 Pen Injectors: Selected Product Comparisons, 2016
Table 5.18 Autoinjectors: Selected Product Comparisons, 2016
Table 5.19 Selected Other Pen Injector and Autoinjector Manufacturers, 2016
Table 5.20 Bespak Injectables Overview, 2016
Table 6.1 Catalent Overview, 2016
Table 6.2 Catalent: Employees by Region, 2016
Table 6.3 Catalent: Revenue by Division ($m), CAGR (%), 2013-2015
Table 6.4 Catalent Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 6.5 Catalent Medication Delivery Solutions Division: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
Table 6.6 Hospira Overview, 2016
Table 6.7 Hospira Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 6.8 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
Table 6.9 Vetter Pharma Overview, 2016
Table 6.10 Vetter Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
Table 6.11 Vetter Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
Table 6.12 Leading Pre-Filled Syringe CMOs: Company Comparison, 2016
Table 6.13 Laboratorios Farmacéuticos ROVI Overview, 2016
Table 6.14 Laboratorios Farmacéuticos ROVI: Revenue ($m), AGR (%), CAGR (%), 2013-2015
Table 6.15 AMRI Overview, 2016
Table 6.16 AMRI: Revenue by Division ($m), AGR (%), CAGR (%), 2013-2015
Table 6.17 Boehringer Ingelheim Overview, 2016
Table 8.1 Leading Pre-Filled Injection Device Manufacturers: Revenue Growth, 2015-2026
List of Figures
Figure 1.1 Global Pre-Filled Injectable Devices Market Segmentation Overview, 2016
Figure 2.1 Total Pre-Filled Device Manufacturing Market Forecast: Revenues ($m), 2015-2026
Figure 2.2 Pre-Filled Injection Device Market by Region, 2015
Figure 3.1 BD Historical Revenue by Division ($m), 2014
Figure 3.2 BD Revenue by Division ($m), 2014-2015
Figure 3.3 BD: Pharmaceutical Systems Revenue ($m), 2013-2015
Figure 3.4 BD Pharmaceutical Systems Revenue Forecast ($m), 2015-2026
Figure 3.5 Gerresheimer: Employees by Region, 2015
Figure 3.6 Gerresheimer: Revenue by Division ($m), 2014-2015
Figure 3.7 Gerresheimer Pen Injectors: Revenue Forecast ($m), 2015-2026
Figure 3.8 Schott Revenue ($m), 2013-2015
Figure 3.9 Unilife: Revenue ($m), 2013-2015
Figure 3.10 Weigao: Pre-Filled Syringes Revenue ($m), 2013-2015
Figure 3.11 Weigao: Revenue Forecast ($m), 2015-2026
Figure 4.1 Aptar Stelmi: Revenue ($m), 2013-2015
Figure 4.2 Aptar Stelmi: Revenue Forecast ($m), 2015-2026
Figure 4.3 Dätwyler: Sealing Solutions Revenue ($m), 2013-2015
Figure 4.4 Dätwyler Healthcare: Revenue Forecast ($m), 2015-2026
Figure 4.5 West: Revenue by Division ($m), 2013-2015
Figure 4.6 West: Pre-Filled Syringe and Device Revenue ($m), 2013-2015
Figure 4.7 West Pharmaceuticals: Revenue Forecast ($m), 2015-2026
Figure 5.1 Ypsomed: Revenue by Division ($m), 2013-2015
Figure 5.2 Ypsomed Delivery Devices: Revenue Forecast ($m), 2015-2026
Figure 6.1 Catalent: Employees by Region, 2016
Figure 6.2 Catalent: Revenue by Division ($m), 2013-2015
Figure 6.3 Catalent Medication Delivery Solutions Division: Revenue Forecast ($m), 2015-2026
Figure 6.4 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
Figure 6.5 Vetter Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
Figure 6.6 Laboratorios Farmacéuticos ROVI: Revenue ($m), 2013-2015
Figure 6.7 AMRI: Revenue by Division ($m), 2013-2015
